ClinicalTrials.gg
Not yet recruitingNCT07409389Updated Feb 13, 2026

Repeated Low-Level Red-Light Therapy in Dry Age-Related Macular Degeneration

An interventional study of RLRL device and Sham device in AMD - Age-Related Macular Degeneration, sponsored by The Hong Kong Polytechnic University. Not yet recruiting at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
39th of 91
94 · median 62
Started
2026
with 8 others
No phase
12 of 107
6 open now
Primary completion
2026-12
later than 23 of 42 live
Registered
100th of 107
by date

Among the 107 studies in Macular Degeneration with a site in China, this one is the 39th largest by planned enrollment of the 91 interventional ones that give a count, is one of 9 that started in 2026, is one of 12 with no phase, reaches primary completion later than 23 of the 42 other live ones, and was the 100th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This prospective, double-blind, randomized controlled trial aims to evaluate the efficacy and safety of repeated low-level red-light (RLRL) therapy in patients with dry age-related macular degeneration (AMD). The primary objective is to assess the effect of RLRL therapy on visual function in patients with dry AMD, while the secondary objective is to evaluate its safety and tolerability.

Seventy-four participants aged 50 years or older with dry AMD will be enrolled and randomly assigned in a 1:1 ratio to either the active RLRL intervention group (using the full device power) or the control group (sham device at 10% power). Group assignments will be masked to both participants and investigators. Participants will administer the treatment at home twice daily (3-minute sessions, with at least a 4-hour interval between sessions) over five consecutive weekdays each month for three months. A video tutorial will guide device usage, with ongoing support from the research team.

Before enrollment, participants will undergo a comprehensive assessment, including ocular and family history review, OCT, and fundus photography to confirm eligibility. Evaluations will occur at baseline, 1 month, and 3 months, covering best-corrected visual acuity (BCVA), slit-lamp examination, OCT, OCT angiography (OCTA), fundus autofluorescence (FAF), contrast sensitivity, color vision, electroretinography (ERG), visual-related quality of life (VRQL) questionnaires, and adverse event monitoring.

The primary outcome is the mean change in BCVA from baseline to 3 months. Secondary outcomes include changes in central drusen thickness, geographic atrophy (GA) size and progression, choroidal blood flow, contrast sensitivity, ERG responses, and VRQL scores.

Given the limited treatment options for dry AMD, which are primarily focused on lifestyle changes and nutritional supplements, this study investigates the potential of RLRL therapy as a novel, non-invasive treatment. The results may address the unmet medical need in dry AMD, potentially slowing disease progression and improving patients' quality of life.

03

Conditions studied

  • AMD - Age-Related Macular Degeneration

Keywords

  • Dry Age-Related Macular Degeneration
  • Red light therapy
  • Visual function
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 50 years old.
  2. Diagnosis of dry AMD in Age-Related Eye Disease Study (AREDS) category 2 to 4, as determined by color fundus photography and fundus autofluorescence imaging. The AREDS categories will be defined as follows:

    i) AREDS category 2 (early AMD): Multiple small drusen, a few intermediate drusen (63-124 μm in diameter), or retinal pigment epithelium (RPE) abnormalities ii) AREDS category 3 (intermediate AMD): Extensive intermediate drusen, including at least one large drusen (> 125 μm in diameter), or geographic atrophy (GA) not involving the center of the fovea.

    iii) AREDS category 4 (advanced/late AMD): GA involving the center of the macula.

    If both eyes meet the inclusion criteria, both eyes will be included in the study analysis.

  3. ETDRS BCVA score between 50 and 75 (Snellen equivalent of 20/32 to 20/100). Willingness to provide written after being informed of the nature of the study.

Exclusion criteria

Exclusion Criteria:

  1. Previous or active neovascular maculopathy.
  2. Presence of center involving GA within the central 500 μm of the ETDRS grid.
  3. Ocular disease other than dry AMD that could cause drusen (glomerulonephritis Type 2, Autosomal dominant drusen), GA (North Carolina macular dystrophy), or mitochondrial disorders (parafoveal petaloid GA, Stargardt disease).
  4. Invasive eye surgery (e.g. cataract extraction, capsulotomy) within 3 months.
  5. Cognitive impairment or history of epilepsy.
  6. Other significant ocular disease affecting visual acuity (e.g., diabetic macular edema, uncontrolled glaucoma, active uveitis, vitreoretinal disease, intraocular tumor, retinal vascular disease, lens opacities more severe than C2, N2, P2 [LOCS III]).

Afterimage > 5 min ( of red-light therapy).

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (estimated)

Study arms

  • Active comparator
    RLRL therapy group

    The RLRL therapy group will undergorepeated low-level red-light therapy (RLRL).The light power through a 4-mm pupil is 0.29 mW for the RLRL device.

    Device: RLRL device

  • Sham comparator
    Sham therapy group

    The sham therapy group will use a sham device, which operates at only 10% of the active RLRL device's power. The light power through a 4-mm pupil is 0.03mW for the sham device.

    Device: Sham device

Interventions

  • DeviceRLRL device

    Each participant in the RLRL therapy group will be provided a repeated low-level red-light therapy (RLRL) device, which they are required to use twice daily for 3minutes per session, with a minimum interval of 4 hours between sessions (5 days a week) for three month.

  • DeviceSham device

    Each participant in the sham group will be provided a sham therapy device, which they are required to use twice daily for 3minutes per session, with a minimum interval of 4 hours between sessions (5 days a week) for three month.

06

What researchers measure

Primary outcomes

  1. The mean change in BCVA measured by ETDRS chart

    An Early Treatment Diabetic Retinopathy Study (ETDRS) chart (Precision Vision, Villa Park, Illinois, USA) with standard illumination will be used to measure distance visual acuity. Best corrected visual acuity and uncorrected visual acuity will be measured.

    Time frame: At 1month and 3 months compared to baseline

Secondary outcomes

  1. Change in central drusen volume measured by optical coherence tomography (OCT)

    Spectral-domain OCT (Spectralis OCT; Heidelberg Engineering, Heidelberg, Germany) with 49 parallel B-scan lines will be used to image the study eye. The automated real-time (ART) function will average 16 frames per scan. Measurements will include sub-RPE macular drusen volume within the 6 × 6 mm ETDRS grid and mean central subfield sub-RPE drusen thickness within the central 1-mm ETDRS subfield. Automated and manually corrected segmentation of Bruch's membrane and the RPE, provided by the Heidelberg software, will be used for analysis.

    Time frame: At 1month and 3 months compared to baseline

  2. Change in central drusen thickness measured by optical coherence tomography (OCT).

    Spectral-domain OCT (Spectralis OCT; Heidelberg Engineering, Heidelberg, Germany) with 49 parallel B-scan lines will be used to image the study eye. The automated real-time (ART) function will average 16 frames per scan. Measurements will include sub-RPE macular drusen volume within the 6 × 6 mm ETDRS grid and mean central subfield sub-RPE drusen thickness within the central 1-mm ETDRS subfield. Automated and manually corrected segmentation of Bruch's membrane and the RPE, provided by the Heidelberg software, will be used for analysis.

    Time frame: At 1month and 3 months compared to baseline

  3. Change in retinal sensitivity using microperimetry.

    Retinal sensitivity will be assessed using microperimetry performed with the MP-3 microperimeter (NIDEK Co., Ltd., Gamagori, Japan). The device will be used to measure localized retinal sensitivity across the macular region following a standardized testing protocol. Retinal sensitivity thresholds and fixation stability parameters will be recorded and analyzed according to the manufacturer's recommendations.

    Time frame: At 1month and 3 months compared to baseline

  4. Outcomes of visual-related quality of life (VRQL) assessed by the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25)

    The 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) will be administered to assess VRQL. This instrument covers 12 subscales: general health, general vision, ocular pain, near vision, distance vision, social functioning, role limitations, mental health, dependency, driving, color vision, and peripheral vision. Each subscale score ranges from 0 to 100, with higher scores indicating better self-reported visual function.

    Time frame: At 3 months compared to baseline

  5. Size of GA assessed by fundus autofluorescence (FAF) imaging

    FAF will be acquired using 488-nm excitation (Spectralis OCT; Heidelberg Engineering, Heidelberg, Germany). GA lesions will be quantified with Region Finder software (Heidelberg Engineering), which provides semi-automated measurement of areas with homogeneous hypoautofluorescence and enables longitudinal assessment of lesion growth.

    Time frame: At 1month and 3 months compared to baseline

  6. Change in contrast sensitivity using the Mars Letter Contrast Sensitivity Test

    The Mars Letter Contrast Sensitivity Test (Mars Perceptrix, Chappaqua, NY, USA) will be performed under standardized photopic lighting at 50 cm. Participants will read letters sequentially from highest to lowest contrast, with contrast decreasing in 0.04 log unit steps. Testing will continue until two consecutive errors are made. Final scores will be calculated per manufacturer's guidelines and expressed in log contrast sensitivity units.

    Time frame: At 1month and 3 months compared to baseline

07

Study locations

1 site
  • The Hong Kong Polytchnic University
    Hong Kong, Hong Kong, China
08

References and documents

Individual participant data

Plan to share: No — According to the relevant agreement, all parties involved must keep study data confidential throughout thestudy process.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2026, 10 months later.

Of 105 non-industry interventional studies with no phase under Macular Degeneration, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 10 months is below that.

Counting every sponsor, half of 133 studies reached it within 37 months; a quarter within 17 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2026
First posted
Feb 13, 2026
StartEst.
Jan 26, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07409389
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Jan 26, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Feb 13, 2026

Study contacts

Mingguang He
Contact
mingguang.he@polyu.edu.hk
85234002795
Yanxian Chen
Contact
yan-xian.chen@polyu.edu.hk
85227666111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion